155 results about "Non competitive" patented technology

The invention discloses non-competitive random access method and equipment on a secondary cell (SCell). The method comprises the following steps: a network side notifies UE (user equipment) to initiate non-competitive random access on the SCell; the network side receives a special preamble from the UE; and the network side sends the scheduling information carrying TA (timing alignment) value information to the UE through the search space of a non-SCell public search space of the UE. In the embodiment of the invention, the UE can initiate a non-competitive random access process on the SCell; and moreover, the UE can finish the random access process on the premise of not monitoring the PDCCH (physical downlink control channel) of the SCell public search space, and can obtain the TA information on the SCell.

The present invention relates to agents that are non-competitive antagonists of the CD94 / NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.

The invention discloses a self-adaptive low-delay media access control method in a WBAN (wireless body area network), mainly solving the problem that a GTS (guaranteed time slot) slot can not realize self-adaptive distribution and has long time delay for ensuring time slot service when IEEE (Institute of Electrical and Electronic Engineers) 802.15.4 is applied to the WBAN. The self-adaptive low-delay media access control method comprises the following realization steps: a coordinating point receives the GTS request of a common node in a competitive period, an inactive period is compressed to expand a non-competitive period, and the GTS time slot is dynamically distributed according to amount requested by GTS; the common node of the obtained GTS time slot finishes GTS service transmission with the coordinating point in the non-competitive period; the coordinating point broadcasts and sends a notification frame in a notification frame time slot after the non-competitive period to notifythe common node to expand the time slot distribution of the non-competitive period; and the common node of the obtained GTS time slot finishes GTS service transmission with the coordinating point in the expanding non-competitive period. Compared with the IEEE 802.15.4, the self-adaptive low-delay media access control method can be used to realize the self-adaptive distribution of the GTS time slot, lower the delay of GTS service grouping, reduce the energy consumption of the coordinating point and is suitable for the WBAN.

The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.

Short enzyme donor fragments of β-galactosidase are provided of not more than 40 amino acids, where the short fragments are used as a label and may be substituted with a wide variety of organic compounds, particularly polypeptides having independent functional activity. The enzyme donor finds use in competitive and non-competitive assays, monitoring intracellular events, or other processes where a sensitive non-interfering label is desired.

Point-of-care assays for quantitatively measuring the amount of small analytes, such as opioids, tetrahydrocannibinol (“THC”), or hormones, in a biological sample are disclosed. The assays are capable of non-competitive detection of a small analyte using binding agents that selectively bind the analyte and capture agents that selectively bind a complex of the binding agent and analyte but do not bind either free binding agent or free analyte. The assay is capable of simultaneous diction of multiple analytes for multiplex analysis and quantitative control. Quantitative measurements are obtained by plotting results against a response surface calculated from a plurality of analyte standards and adjusted using internal controls.

Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.

A non-competitive immunoassay for small analytes, wherein the analyte is reacted with two binding partners. The first binding partner binds to the analyte to form a complex between the first binding partner and the analyte, and the second binding partner binds to the complex formed by the first binding partner and the analyte. The resulting complex formed between the analyte and the binding partners is detected. The binding partners are proteins, such as antibodies including antibody fragments.